These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9414255)

  • 21. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
    Mini E; Moroson BA; Franco CT; Bertino JR
    Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.
    McMillin DW; Hewes B; Gangadharan B; Archer DR; Mittler RS; Spencer HT
    Hum Gene Ther; 2006 Aug; 17(8):798-806. PubMed ID: 16942440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells.
    Allay JA; Galipeau J; Blakley RL; Sorrentino BP
    Stem Cells; 1998; 16 Suppl 1():223-33. PubMed ID: 11012166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations leading to antifolate resistance in Chinese hamster ovary cells after exposure to the alkylating agent ethylmethanesulfonate.
    Fanin R; Banerjee D; Volkenandt M; Waltham M; Li WW; Dicker AP; Schweitzer BI; Bertino JR
    Mol Pharmacol; 1993 Jul; 44(1):13-21. PubMed ID: 8341268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase.
    Volpato JP; Fossati E; Pelletier JN
    J Mol Biol; 2007 Oct; 373(3):599-611. PubMed ID: 17868689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
    Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ternary crystal complexes of F31 variants of human dihydrofolate reductase with NADPH and a classical antitumor furopyrimidine.
    Cody V; Galitsky N; Luft JR; Pangborn W; Blakley RL; Gangjee A
    Anticancer Drug Des; 1998 Jun; 13(4):307-15. PubMed ID: 9627670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
    Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
    Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drosophila dihydrofolate reductase mutations confer antifolate resistance to mammalian cells.
    Affleck JG; Al-Batayneh KM; Neumann K; Cole SP; Walker VK
    Eur J Pharmacol; 2006 Jan; 529(1-3):71-8. PubMed ID: 16325803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometric characterization of antifolate resistance in cultured mammalian cells using fluoresceinated methotrexate and daunorubicin.
    Sherwood SW; Assaraf YG; Molina A; Schimke RT
    Cancer Res; 1990 Aug; 50(16):4946-50. PubMed ID: 2143099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection for methotrexate resistance in mammalian cells bearing a Drosophila dihydrofolate reductase transgene: Methotrexate resistance in transgenic mammalian cells.
    Affleck JG; Nowickyj SM; Walker VK
    Cell Biol Toxicol; 2010 Apr; 26(2):117-26. PubMed ID: 19337845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active site-directed double mutants of dihydrofolate reductase.
    Ercikan-Abali EA; Mineishi S; Tong Y; Nakahara S; Waltham MC; Banerjee D; Chen W; Sadelain M; Bertino JR
    Cancer Res; 1996 Sep; 56(18):4142-5. PubMed ID: 8797582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allelic variation in the dihydrofolate reductase gene at amino acid position 95 contributes to antifolate resistance in Chinese hamster cells.
    Yu M; Melera PW
    Cancer Res; 1993 Dec; 53(24):6031-5. PubMed ID: 8261418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype.
    Assaraf YG; Borgnia MJ
    Anticancer Drugs; 1993 Jun; 4(3):395-406. PubMed ID: 8102912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates.
    Fry DW; Besserer JA
    Cancer Res; 1988 Dec; 48(24 Pt 1):6986-91. PubMed ID: 2973370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifolate resistance and its circumvention by new analogues.
    Takemura Y; Kobayashi H; Miyachi H
    Hum Cell; 2001 Sep; 14(3):185-202. PubMed ID: 11774738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
    Sweeney CL; Frandsen JL; Verfaillie CM; McIvor RS
    Cancer Res; 2003 Mar; 63(6):1304-10. PubMed ID: 12649191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance.
    Volpato JP; Yachnin BJ; Blanchet J; Guerrero V; Poulin L; Fossati E; Berghuis AM; Pelletier JN
    J Biol Chem; 2009 Jul; 284(30):20079-89. PubMed ID: 19478082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
    Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
    J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.